Literature DB >> 23298609

T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment.

Joel Crespo1, Haoyu Sun, Theodore H Welling, Zhigang Tian, Weiping Zou.   

Abstract

Human tumors progress despite the presence of tumor associated antigen (TAA)-specific T cells. Many different molecular and cellular mechanisms contribute to the failure of T cells to eradicate the tumor. These include immune suppressive networks that impair ongoing T cell function and enable tumor escape. Recent studies have started to reveal the nature of effector T cells in the tumor microenvironment. In this article we discuss T cell anergy, exhaustion, senescence, and stemness, and review the phenotype of dysfunctional T cell subsets and the underlying molecular mechanisms in the tumor microenvironments. We suggest that targeting T cell dysfunctional mechanisms and introducing/promoting T cell stemness are important approaches to treat patients with cancer.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23298609      PMCID: PMC3636159          DOI: 10.1016/j.coi.2012.12.003

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  76 in total

1.  CTLA-4 regulates induction of anergy in vivo.

Authors:  R J Greenwald; V A Boussiotis; R B Lorsbach; A K Abbas; A H Sharpe
Journal:  Immunity       Date:  2001-02       Impact factor: 31.745

2.  Calcium oscillations increase the efficiency and specificity of gene expression.

Authors:  R E Dolmetsch; K Xu; R S Lewis
Journal:  Nature       Date:  1998-04-30       Impact factor: 49.962

3.  Analysis of sirtuin 1 expression reveals a molecular explanation of IL-2-mediated reversal of T-cell tolerance.

Authors:  Beixue Gao; Qingfei Kong; Kyeorda Kemp; Yuan-Si Zhao; Deyu Fang
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-04       Impact factor: 11.205

4.  Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells.

Authors:  Jason M Brenchley; Nitin J Karandikar; Michael R Betts; David R Ambrozak; Brenna J Hill; Laura E Crotty; Joseph P Casazza; Janaki Kuruppu; Stephen A Migueles; Mark Connors; Mario Roederer; Daniel C Douek; Richard A Koup
Journal:  Blood       Date:  2002-11-14       Impact factor: 22.113

5.  Viral infections induce abundant numbers of senescent CD8 T cells.

Authors:  D Voehringer; C Blaser; P Brawand; D H Raulet; T Hanke; H Pircher
Journal:  J Immunol       Date:  2001-11-01       Impact factor: 5.422

6.  Human TH17 cells are long-lived effector memory cells.

Authors:  Ilona Kryczek; Ende Zhao; Yan Liu; Yin Wang; Linhua Vatan; Wojciech Szeliga; Jeffrey Moyer; Aleksandra Klimczak; Andrzej Lange; Weiping Zou
Journal:  Sci Transl Med       Date:  2011-10-12       Impact factor: 17.956

7.  Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion.

Authors:  Xiaoyuan Huang; Xiangyang Bai; Yang Cao; Jingyi Wu; Mei Huang; Duozhuang Tang; Si Tao; Tao Zhu; Yanling Liu; Yang Yang; Xiaoxi Zhou; Yanxia Zhao; Mingfu Wu; Juncheng Wei; Daowen Wang; Gang Xu; Shixuan Wang; Ding Ma; Jianfeng Zhou
Journal:  J Exp Med       Date:  2010-02-22       Impact factor: 14.307

8.  Tumor-induced senescent T cells with suppressor function: a potential form of tumor immune evasion.

Authors:  Carolina L Montes; Andrei I Chapoval; Jonas Nelson; Vbenosa Orhue; Xiaoyu Zhang; Dan H Schulze; Scott E Strome; Brian R Gastman
Journal:  Cancer Res       Date:  2008-02-01       Impact factor: 12.701

9.  BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination.

Authors:  Laurent Derré; Jean-Paul Rivals; Camilla Jandus; Sonia Pastor; Donata Rimoldi; Pedro Romero; Olivier Michielin; Daniel Olive; Daniel E Speiser
Journal:  J Clin Invest       Date:  2009-12-28       Impact factor: 14.808

10.  PD-1 and BTLA and CD8(+) T-cell "exhaustion" in cancer: "Exercising" an alternative viewpoint.

Authors:  Cara Haymaker; Richard Wu; Chantale Bernatchez; Laszlo Radvanyi
Journal:  Oncoimmunology       Date:  2012-08-01       Impact factor: 8.110

View more
  268 in total

Review 1.  New Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target Malignancies.

Authors:  Thomas M Schmitt; Ingunn M Stromnes; Aude G Chapuis; Philip D Greenberg
Journal:  Clin Cancer Res       Date:  2015-10-13       Impact factor: 12.531

2.  Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer.

Authors:  Edmund K Moon; Raghuveer Ranganathan; Evgeniy Eruslanov; Soyeon Kim; Kheng Newick; Shaun O'Brien; Albert Lo; Xiaojun Liu; Yangbing Zhao; Steven M Albelda
Journal:  Clin Cancer Res       Date:  2015-08-31       Impact factor: 12.531

3.  CTLA4 Promotes Tyk2-STAT3-Dependent B-cell Oncogenicity.

Authors:  Andreas Herrmann; Christoph Lahtz; Toshikage Nagao; Joo Y Song; Wing C Chan; Heehyoung Lee; Chanyu Yue; Thomas Look; Ronja Mülfarth; Wenzhao Li; Kurt Jenkins; John Williams; Lihua E Budde; Stephen Forman; Larry Kwak; Thomas Blankenstein; Hua Yu
Journal:  Cancer Res       Date:  2017-07-17       Impact factor: 12.701

4.  Resident T Cells Are Unable To Control Herpes Simplex Virus-1 Activity in the Brain Ependymal Region during Latency.

Authors:  Chandra M Menendez; Jeremy K Jinkins; Daniel J J Carr
Journal:  J Immunol       Date:  2016-06-29       Impact factor: 5.422

Review 5.  Human cell-based artificial antigen-presenting cells for cancer immunotherapy.

Authors:  Marcus O Butler; Naoto Hirano
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

6.  Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis.

Authors:  Andrea Schietinger; Mary Philip; Varintra E Krisnawan; Edison Y Chiu; Jeffrey J Delrow; Ryan S Basom; Peter Lauer; Dirk G Brockstedt; Sue E Knoblaugh; Günter J Hämmerling; Todd D Schell; Natalio Garbi; Philip D Greenberg
Journal:  Immunity       Date:  2016-08-09       Impact factor: 31.745

Review 7.  Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy.

Authors:  Anne M Macpherson; Simon C Barry; Carmela Ricciardelli; Martin K Oehler
Journal:  J Clin Med       Date:  2020-09-14       Impact factor: 4.241

Review 8.  Heart failure in cancer: role of checkpoint inhibitors.

Authors:  Murilo Delgobo; Stefan Frantz
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

9.  Functional exhaustion of CD4+ T cells induced by co-stimulatory signals from myeloid leukaemia cells.

Authors:  Didem Ozkazanc; Digdem Yoyen-Ermis; Ece Tavukcuoglu; Yahya Buyukasik; Gunes Esendagli
Journal:  Immunology       Date:  2016-09-29       Impact factor: 7.397

10.  Tumor-specific IL-9-producing CD8+ Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers.

Authors:  Yong Lu; Bangxing Hong; Haiyan Li; Yuhuan Zheng; Mingjun Zhang; Siqing Wang; Jianfei Qian; Qing Yi
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.